Ranbaxy Laboratories’ arm gets USFDA nod for Absorica

Ranbaxy Laboratories’ wholly owned subsidiary Ranbaxy Laboratories Inc (RLI) has received US Food and Drug Administration (USFDA) approval for Absorica, a novel, patented brand formulation of the acne medication isotretinoin, developed by Cipher, for the treatment of severe recalcitrant nodular acne.

Through a business agreement with the Canadian firm, Cipher Pharmaceutical Inc, RLI is expected to launch Absorica in the US in Q4 2012; as per the agreement, Ranbaxy will pay royalties on net sales to Cipher.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.